MSI Detection (bioSkills)
A Claude Code skill that calls microsatellite instability status from sequencing data — paired, tumour-only or cfDNA — with the panel-specific thresholds each caller actually requires.
| Type | Claude Skill |
| Supplier | GPTomics bioSkills (community OSS, MIT) |
| Availability | GA — part of the bioSkills collection |
| Pricing | Free / OSS (MIT). MSIsensor, MSIsensor-pro, MSIsensor-ct, MANTIS and mSINGS are separately installed command-line tools under their own licences |
| Capabilities | Read/Write — Claude drives the CLI tools locally on your BAMs; it is not an MCP tool |
| Verified | works · 2026-08-17 |
| Security | caution · 2026-08-17 — GPTomics/bioSkills is now archived upstream; MIT and skill dir confirmed unchanged |
How to install
bioSkills is not an npm package — skills are plain markdown/code read directly by the agent. Clone the repo, then either run the installer for the whole category or copy the single skill directory.
- Claude Code — clone and install via the bundled script:
git clone https://github.com/GPTomics/bioSkills cd bioSkills ./install-claude.sh --categories "clinical-databases"The installer copies matching skills into
~/.claude/skills/(default target). Use./install-claude.sh --listto preview the skills first. - Claude Code / other agents — copy just this one skill:
cp -r bioSkills/clinical-databases/msi-detection ~/.claude/skills/(run from the directory holding your clone — if you are still in
bioSkills/from the previous step, usecp -r clinical-databases/msi-detection ~/.claude/skills/, or replacebioSkills/with the absolute path of your clone). Install the primary caller:conda install -c bioconda msisensor-pro(bioconda is the documented distribution route for MSIsensor-pro; MANTIS and mSINGS install from their own repositories.)
What it does
Chooses the caller that matches the data you actually have, then applies its calibrated cutoff:
- MSIsensor — paired tumour–normal, the reference case.
- MSIsensor-pro — tumour-only, using a population baseline built from a cohort of normals.
- MSIsensor-ct — cfDNA and liquid biopsy, panel-aware.
- MANTIS — step-wise difference algorithm (> 0.4 instability threshold).
- mSINGS — background-panel approach for targeted panels.
Reported thresholds and gates:
| Parameter | Value |
|---|---|
| MSI-H | ≥ 20–30% unstable loci (panel-calibrated) |
| Bethesda 5-locus panel | ≥ 2/5 unstable = 40% |
| Minimum informative loci | ≥ 50 for NGS-derived site sets |
| Tumour purity | ≥ 20% |
| ctDNA fraction (MSIsensor-ct) | ≥ 3% |
| MANTIS step-wise difference | > 0.4 |
Output is the raw unstable-locus count, the percentage unstable, and an MSI-H / MSI-L / MSS classification, with concordance checks against MMR immunohistochemistry.
Primary use cases: checkpoint-inhibitor eligibility (FDA pembrolizumab pan-tumour MSI-H, 2017; KEYNOTE-177), Lynch syndrome screening, dMMR confirmation, liquid-biopsy MSI.
Notes
Research use, not a diagnostic result — clinical MSI status comes from a validated assay plus MMR IHC, and the skill’s own workflow treats IHC concordance as a required cross-check rather than an optional one.
Two failure modes it is explicit about: a tumour-only call without a properly matched population baseline is unreliable, and low tumour purity or low ctDNA fraction produces false-MSS results rather than a flagged failure. Distinguishing MSI-H from a POLE-exonuclease hypermutator matters clinically because the mutational signatures overlap.
Read alongside Tumor Mutational Burden — MSI-H and TMB-H are correlated but separately reported ICI biomarkers (Sha 2020, Salem 2018) — and Somatic Signatures for MMR-deficiency versus POLE etiology.
Distributed as a SKILL.md (plus reference material) in the bioSkills collection. Upstream skill front-matter name is bio-clinical-databases-msi-detection; upstream directory clinical-databases/msi-detection. The skill is description-activated — there is no bare /msi-detection slash command.
Sources
GPTomics/bioSkillsclinical-databases/msi-detection/SKILL.mdxjtu-omics/msisensor-pro- FDA approval of pembrolizumab for MSI-H/dMMR solid tumours (2017)
- Le et al. 2015, PD-1 blockade in mismatch-repair-deficient tumours
Installed this tool?
Share feedback — install path, OS, errors, workarounds. The form opens with this tool pre-selected and a link back to this page.